ATE419524T1 - Krebsbehandlung - Google Patents

Krebsbehandlung

Info

Publication number
ATE419524T1
ATE419524T1 AT03744916T AT03744916T ATE419524T1 AT E419524 T1 ATE419524 T1 AT E419524T1 AT 03744916 T AT03744916 T AT 03744916T AT 03744916 T AT03744916 T AT 03744916T AT E419524 T1 ATE419524 T1 AT E419524T1
Authority
AT
Austria
Prior art keywords
agent
cancer
cell sample
function
effective
Prior art date
Application number
AT03744916T
Other languages
English (en)
Inventor
Hilmar Meek Warenius
Philip Spencer Rudland
Laurence Anthony Seabra
Original Assignee
Theryte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0207031A external-priority patent/GB0207031D0/en
Priority claimed from GB0223325A external-priority patent/GB2387385A/en
Application filed by Theryte Ltd filed Critical Theryte Ltd
Application granted granted Critical
Publication of ATE419524T1 publication Critical patent/ATE419524T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03744916T 2002-03-25 2003-03-25 Krebsbehandlung ATE419524T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0207031A GB0207031D0 (en) 2002-03-25 2002-03-25 Treating cancer
GB0216634A GB0216634D0 (en) 2002-03-25 2002-07-17 Treating cancer
GB0223325A GB2387385A (en) 2002-03-25 2002-10-08 Chemotherapeutic agents for treating cancer

Publications (1)

Publication Number Publication Date
ATE419524T1 true ATE419524T1 (de) 2009-01-15

Family

ID=28457507

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03744916T ATE419524T1 (de) 2002-03-25 2003-03-25 Krebsbehandlung

Country Status (7)

Country Link
US (1) US7989176B2 (de)
EP (1) EP1502107B1 (de)
AT (1) ATE419524T1 (de)
AU (1) AU2003215762A1 (de)
DE (1) DE60325579D1 (de)
ES (1) ES2320437T3 (de)
WO (1) WO2003081239A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0413346D0 (en) * 2004-06-15 2004-07-21 Theryte Ltd Treating cancer
GB0804496D0 (en) 2008-03-11 2008-04-16 Theryte Ltd Treating cancer
GB0805141D0 (en) * 2008-03-19 2008-04-23 Theryte Ltd Companion diagnostic for cancer
WO2010132958A1 (en) * 2009-05-22 2010-11-25 Garvan Institute Of Medical Research Methods for predicting responsiveness to treatment
CN102296067B (zh) * 2011-07-07 2015-04-15 中国人民解放军军事医学科学院放射与辐射医学研究所 靶向cdk1抗ev71、登革、乙脑及流感病毒寡核苷酸的结构和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962316A (en) * 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US6004939A (en) * 1995-07-06 1999-12-21 Ctrc Research Foundation Board Of Regents Methods for modulation and inhibition of telomerase
EP0977738B1 (de) * 1997-04-28 2005-11-16 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Cyclin abhängige kinase(cdk)4 hemmer und deren verwendung zur behandlung von krebs
WO1999027087A1 (en) * 1997-11-21 1999-06-03 Hybridon, Inc. Antisense oligonucleotides specific for cdk4
DE69907153T2 (de) * 1998-02-18 2004-01-29 Theryte Ltd Krebsbehandlung
JP4282163B2 (ja) * 1999-07-12 2009-06-17 株式会社医学生物学研究所 癌転移能検査方法、および癌転移抑制薬のスクリーニング方法
WO2002016939A2 (en) * 2000-08-18 2002-02-28 Eos Biotechnology, Inc. Methods of diagnosis of cancer and screening for cancer modulators

Also Published As

Publication number Publication date
US20060003329A1 (en) 2006-01-05
DE60325579D1 (de) 2009-02-12
EP1502107A2 (de) 2005-02-02
AU2003215762A1 (en) 2003-10-08
ES2320437T3 (es) 2009-05-22
WO2003081239A3 (en) 2004-09-16
EP1502107B1 (de) 2008-12-31
WO2003081239A2 (en) 2003-10-02
US7989176B2 (en) 2011-08-02

Similar Documents

Publication Publication Date Title
TW200736231A (en) Substituted pyrimidines
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
WO2002056022A3 (en) Diagnostics, drug screening and treatment for cancer
WO2005084109A3 (en) Cancer specific gene mh15
Iannone et al. Effect of surgery on pancreatic tumor-dependent lymphocyte asset: modulation of natural killer cell frequency and cytotoxic function
MXPA06011046A (es) Ciertos compuestos basados en triazol, composiciones, y usos de los mismos.
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
TW200634309A (en) Tubulin isotype screening in cancer therapy using halichondrin b analogs
SI2492355T1 (sl) Tkivno protektivni eritropoetinski receptor (nepor) in postopki uporabe
WO2001052904A3 (en) Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides
WO2006067465A3 (en) Cancer treatment
MX2010006090A (es) Biomarcadores para predecir la sensibilidad de las celulas ante compuestos inmunomoduladores durante el tratamiento de linfoma de no hodgkin.
WO2008106594A3 (en) Inhibitors of nucleophosmin (npm) and methods for inducing apoptosis
TW200716132A (en) Novel chemical compounds
ATE478076T1 (de) Azaxanthonen zur behandlung von tumoren
DK2215274T3 (da) Middel og fremgangsmåde til at garve huder og pelse
AU2385095A (en) Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
Shibata et al. Disturbed expression of the apoptosis regulators XIAP, XAF1, and Smac/DIABLO in gastric adenocarcinomas
DE60325579D1 (de) Krebsbehandlung
WO2005005661A3 (en) Genes regulated in ovarian cancer as prognostic and therapeutic targets
WO2001062784A3 (en) Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
TW200502349A (en) Electroluminecence material and refining method thereof and electroluminecence device
WO2005019269A3 (en) Techniques and compositions for the diagnosis and treatment of cancer (muc1)
WO2009023846A3 (en) Methods for heat shock protein dependent cancer treatment
Mancini et al. Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties